Tom 10, Nr 1 (2018)
Artykuły
Opublikowany online: 2018-08-13
Wyświetlenia strony
1581
Wyświetlenia/pobrania artykułu
9550
Ostra biegunka
Gastroenterologia Kliniczna 2018;10(1):14-22.
Streszczenie
Z uwagi na utrzymującą się od lat wysoką chorobowość, ostre biegunki są powszechnym i istotnym problemem klinicznym, nawet krajach rozwiniętych. Chociaż całkowita śmiertelność z powodu ostrej biegunki jest niska, to w grupie chorych powyżej 80. rż. może sięgać 3%. Najczęstszym czynnikiem etiologicznym ostrej biegunki są wirusy, rzadszym bakterie i pierwotniaki. Większość ostrych biegunek ma charakter samoograniczający się i wymaga jedynie leczenia objawowego. Wskazaniem do pogłębienia diagnostyki w celu identyfikacji patogenu są: biegunki inwazyjne, objawiające się gorączką, silnymi bólami brzucha i krwistymi stolcami, istnienie czynników ryzyka powikłań u pacjenta oraz powody epidemiologiczne. W artykule omówiono zagadnienia dotyczące diagnostyki oraz leczenia ostrych biegunek — zarówno objawowego, jak i antybiotykoterapii a także profilaktykę biegunek podróżnych i poantybiotykowych.
Słowa kluczowe: brak
Referencje
- (WHO) WHO. Diarrhoea. http://www.who.int/topics/diarrhoea/en/ (20.06.2018).
- Farthing M, Salam MA, Lindberg G, et al. WGO. Acute diarrhea in adults and children: a global perspective. J Clin Gastroenterol. 2013; 47(1): 12–20.
- Gangarosa RE, Glass RI, Lew JF, et al. Hospitalizations involving gastroenteritis in the United States, 1985: the special burden of the disease among the elderly. Am J Epidemiol. 1992; 135(3): 281–290.
- Bresee JS, Marcus R, Venezia RA, et al. US Acute Gastroenteritis Etiology Study Team. The etiology of severe acute gastroenteritis among adults visiting emergency departments in the United States. J Infect Dis. 2012; 205(9): 1374–1381.
- Hilmarsdóttir I, Baldvinsdóttir GE, Harðardóttir H, et al. Enteropathogens in acute diarrhea: a general practice-based study in a Nordic country. Eur J Clin Microbiol Infect Dis. 2012; 31(7): 1501–1509.
- Maragkoudakis S, Poulidaki SR, Papadomanolaki E, et al. Empiric antimicrobial therapy and infectious diarrhea. Do we need local guidelines? Eur J Intern Med. 2011; 22(5): e60–e62.
- Amar CFL, East CL, Gray J, et al. Detection by PCR of eight groups of enteric pathogens in 4,627 faecal samples: re-examination of the English case-control Infectious Intestinal Disease Study (1993-1996). Eur J Clin Microbiol Infect Dis. 2007; 26(5): 311–323.
- Shane AL, Mody RK, Crump JA, et al. 2017 Infectious Diseases Society of America Clinical Practice Guidelines for the Diagnosis and Management of Infectious Diarrhea. Clin Infect Dis. 2017; 65(12): 1963–1973.
- Eurosurveillance editorial team. The 2013 joint ECDC/EFSA report on trends and sources of zoonoses, zoonotic agents and food-borne outbreaks published. Euro Surveill. 2015; 20(4).
- Riddle MS, DuPont HL, Connor BA. ACG Clinical Guideline: Diagnosis, Treatment, and Prevention of Acute Diarrheal Infections in Adults. Am J Gastroenterol. 2016; 111(5): 602–622.
- Rozporządzenie Ministra Zdrowia z dnia 10 lipca 2013 r. w sprawie zgłoszeń podejrzenia lubrozpoznania zakażenia, choroby zakaźnej lub zgonu z powodu zakażenia lub choroby zakaźnej. Dziennik Ustaw 2013.
- Panos GZ, Betsi GI, Falagas ME. Systematic review: are antibiotics detrimental or beneficial for the treatment of patients with Escherichia coli O157:H7 infection? Aliment Pharmacol Ther. 2006; 24(5): 731–742.
- Marshall JK, Thabane M, Garg AX, et al. Walkerton Health Study Investigators, Walkerton Health Study Investigators. Incidence and epidemiology of irritable bowel syndrome after a large waterborne outbreak of bacterial dysentery. Gastroenterology. 2006; 131(2): 445–50; quiz 660.
- Allos BM. Campylobacter jejuni Infections: update on emerging issues and trends. Clin Infect Dis. 2001; 32(8): 1201–1206.
- Koo HL, Koo DC, Musher DM, et al. Antimotility agents for the treatment of Clostridium difficile diarrhea and colitis. Clin Infect Dis. 2009; 48(5): 598–605.
- Hughes A, Hendrickson RG, Chen BCC, et al. Severe loperamide toxicity associated with the use of cimetidine to potentiate the "high". Am J Emerg Med. 2018 [Epub ahead of print].
- DuPont HL. Bismuth subsalicylate in the treatment and prevention of diarrheal disease. Drug Intell Clin Pharm. 1987; 21(9): 687–693.
- Salazar-Lindo E, Santisteban-Ponce J, Chea-Woo E, et al. Racecadotril in the treatment of acute watery diarrhea in children. N Engl J Med. 2000; 343(7): 463–467.
- Wang HH, Shieh MJ, Liao KF. A blind, randomized comparison of racecadotril and loperamide for stopping acute diarrhea in adults. World J Gastroenterol. 2005; 11(10): 1540–1543.
- Buccigrossi V, Russo C, Guarino A, et al. Mechanisms of antidiarrhoeal effects by diosmectite in human intestinal cells. Gut Pathog. 2017; 9: 23.
- González R, de Medina FS, Martínez-Augustin O, et al. Anti-inflammatory effect of diosmectite in hapten-induced colitis in the rat. Br J Pharmacol. 2004; 141(6): 951–960.
- Hu C, Song J, Li Y, et al. Diosmectite-zinc oxide composite improves intestinal barrier function, modulates expression of pro-inflammatory cytokines and tight junction protein in early weaned pigs. Br J Nutr. 2013; 110(4): 681–688.
- Khediri F, Mrad AI, Azzouz M, et al. Efficacy of diosmectite (smecta) in the treatment of acute watery diarrhoea in adults: a multicentre, randomized, double-blind, placebo-controlled, parallel group study. Gastroenterol Res Pract. 2011; 2011: 783196.
- Szajewska H, Dziechciarz P, Mrukowicz J. Meta-analysis: Smectite in the treatment of acute infectious diarrhoea in children. Aliment Pharmacol Ther. 2006; 23(2): 217–227.
- Dunne C, O'Mahony L, Murphy L, et al. In vitro selection criteria for probiotic bacteria of human origin: correlation with in vivo findings. Am J Clin Nutr. 2001; 73(2 Suppl): 386S–392S.
- Szajewska H, Guarino A, Hojsak I, et al. European Society for Pediatric Gastroenterology, Hepatology, and Nutrition. Use of probiotics for management of acute gastroenteritis: a position paper by the ESPGHAN Working Group for Probiotics and Prebiotics. J Pediatr Gastroenterol Nutr. 2014; 58(4): 531–539.
- Onwuezobe IA, Oshun PO, Odigwe CC. Antimicrobials for treating symptomatic non-typhoidal Salmonella infection. Cochrane Database Syst Rev. 2012; 11: CD001167.
- De Bruyn G, Hahn S, Borwick A. Antibiotic treatment for travellers' diarrhoea. Cochrane Database Syst Rev. 2000(3): CD002242.
- Graham DY, Estes MK, Gentry LO. Double-blind comparison of bismuth subsalicylate and placebo in the prevention and treatment of enterotoxigenic Escherichia coli-induced diarrhea in volunteers. Gastroenterology. 1983; 85(5): 1017–1022.
- Kollaritsch H, Holst H, Grobara P, et al. Prevention of traveler's diarrhea with Saccharomyces boulardii. Results of a placebo controlled double-blind study. Fortschr Med. 1993; 111(9): 152–156.
- Krokowicz L, Kaczmarek BF, Krokowicz P, et al. Sodium butyrate and short chain fatty acids in prevention of travellers' diarrhoea: a randomized prospective study. Travel Med Infect Dis. 2014; 12(2): 183–188.
- Alajbegovic S, Sanders JW, Atherly DE, et al. Effectiveness of rifaximin and fluoroquinolones in preventing travelers' diarrhea (TD): a systematic review and meta-analysis. Syst Rev. 2012; 1: 39.
- Hempel S, Newberry SJ, Maher AR, et al. Probiotics for the prevention and treatment of antibiotic-associated diarrhea: a systematic review and meta-analysis. JAMA. 2012; 307(18): 1959–1969.
- McFarland LV. Systematic review and meta-analysis of Saccharomyces boulardii in adult patients. World J Gastroenterol. 2010; 16(18): 2202–2222.
- Malfertheiner P, Megraud F, O'Morain CA, et al. European Helicobacter and Microbiota Study Group and Consensus panel. Management of Helicobacter pylori infection-the Maastricht V/Florence Consensus Report. Gut. 2017; 66(1): 6–30.
- de Gunzburg J, Ghozlane A, Ducher A, et al. Protection of the human gut microbiome from antibiotics. J Infect Dis. 2018; 217(4): 628–636.
